These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 15799239)

  • 21. [PI3K-AKT-mTOR pathway inhibitors].
    Cortot A; Armand JP; Soria JC
    Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current development of mTOR inhibitors as anticancer agents.
    Faivre S; Kroemer G; Raymond E
    Nat Rev Drug Discov; 2006 Aug; 5(8):671-88. PubMed ID: 16883305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas.
    Nakamura JL; Karlsson A; Arvold ND; Gottschalk AR; Pieper RO; Stokoe D; Haas-Kogan DA
    J Neurooncol; 2005 Feb; 71(3):215-22. PubMed ID: 15735908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
    Shi Y; Gera J; Hu L; Hsu JH; Bookstein R; Li W; Lichtenstein A
    Cancer Res; 2002 Sep; 62(17):5027-34. PubMed ID: 12208757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
    Grünwald V; DeGraffenried L; Russel D; Friedrichs WE; Ray RB; Hidalgo M
    Cancer Res; 2002 Nov; 62(21):6141-5. PubMed ID: 12414639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
    Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
    Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overcoming endocrine therapy resistance by signal transduction inhibition.
    Ellis M
    Oncologist; 2004; 9 Suppl 3():20-6. PubMed ID: 15163844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
    Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.
    Carraway H; Hidalgo M
    Breast Cancer Res; 2004; 6(5):219-24. PubMed ID: 15318929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy.
    Mills GB; Lu Y; Fang X; Wang H; Eder A; Mao M; Swaby R; Cheng KW; Stokoe D; Siminovitch K; Jaffe R; Gray J
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):125-41. PubMed ID: 11706404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents.
    Rao RD; Buckner JC; Sarkaria JN
    Curr Cancer Drug Targets; 2004 Dec; 4(8):621-35. PubMed ID: 15578919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Scientists hopeful as they uncover molecular clues to prostate cancer.
    Vanchieri C
    J Natl Cancer Inst; 2005 Feb; 97(3):168-9. PubMed ID: 15687357
    [No Abstract]   [Full Text] [Related]  

  • 34. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.
    Ozes ON; Akca H; Mayo LD; Gustin JA; Maehama T; Dixon JE; Donner DB
    Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4640-5. PubMed ID: 11287630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of translation initiation by FRAP/mTOR.
    Gingras AC; Raught B; Sonenberg N
    Genes Dev; 2001 Apr; 15(7):807-26. PubMed ID: 11297505
    [No Abstract]   [Full Text] [Related]  

  • 36. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.
    Weigelt B; Warne PH; Downward J
    Oncogene; 2011 Jul; 30(29):3222-33. PubMed ID: 21358673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.
    Mancini M; Petta S; Martinelli G; Barbieri E; Santucci MA
    J Cell Biochem; 2010 Feb; 109(2):320-8. PubMed ID: 20014066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
    Neshat MS; Mellinghoff IK; Tran C; Stiles B; Thomas G; Petersen R; Frost P; Gibbons JJ; Wu H; Sawyers CL
    Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10314-9. PubMed ID: 11504908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.
    Galanis E; Buckner JC; Maurer MJ; Kreisberg JI; Ballman K; Boni J; Peralba JM; Jenkins RB; Dakhil SR; Morton RF; Jaeckle KA; Scheithauer BW; Dancey J; Hidalgo M; Walsh DJ;
    J Clin Oncol; 2005 Aug; 23(23):5294-304. PubMed ID: 15998902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting PI3K-AKT pathway for cancer therapy.
    Lu Y; Wang H; Mills GB
    Rev Clin Exp Hematol; 2003 Jun; 7(2):205-28. PubMed ID: 14763163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.